**HIV CareLink Newsletter**

National Clinicians’ Post-Exposure Prophylaxis hotline

1888-HIV-8765 (448-8765)

Providing state-of-the-art HIV education, information to assist in individual treatment decisions for their pt.

Also available:

- Oral Manifestations Associated with HIV/AIDS
- 22. Insufficient data in ARV-naïve
- 10. Risks of PI and QT prolongation, baseline ECG before dose. Do not use PrA ART < 400 millivolts (mV), whatever < 50 mV, to avoid therapy that might cause complete AV block without pacemaker, risk of complete AV block
- CIII
- 6. LPV/r (twice daily) + ZDV + 3TC preferred regimen for pregnant women. Once daily lopinavir/r not recommended in pregnant
- 21. Class A: Score 5-Class B: Score 4- Class C: Score 9
- 8. 3. Significant interaction with protein pump inhibitors and other acid-reducing agents. See table under the Atazanavir section.
- 18. Do not use ABC in pts who feel: (for HIV-8765) use caution in pts with high CVD risk or pre-ART viral load < 100,000 copies/mL.
- 19. There are no hepatic dose adjustment recommendations for other NRTIs, see dosing for individual agents
- 5. 2. Do not use EFV in 1st trimester of pregnancy or in sexually active
- 4. 1. See Table 2 of DHHS guidelines for Rating Scheme for strength of recommendations/quality of evidence.
- 12. The information contained in this publication is intended for medical professionals. If a serious adverse event occurs, please alert the
- 22. Insufficient data in ARV-naïve
- 10. Risks of PI and QT prolongation, baseline ECG before dose. Do not use PrA ART < 400 millivolts (mV), whatever < 50 mV, to avoid therapy that might cause complete AV block without pacemaker, risk of complete AV block
- 11.0 only with pre-ART CDL 70 or greater; or previously used CrCl or CAPD: (EC) 125 mg every 24 hrs;
- 13.4 or C: contraindicated
- 14. 1. See Table 2 of DHHS guidelines for Rating Scheme for strength of recommendations/quality of evidence.
- 1. Do not use EFV in 1st trimester of pregnancy or in sexually active
- 2. Do not use EFV in 1st trimester of pregnancy or in sexually active
- 3. Do not use ABC in pts who feel: (for HIV-8765) use caution in pts with high CVD risk or pre-ART viral load < 100,000 copies/mL.
- 4. Use NVG and ABC together since both can cause HSLS, early virologic failure and 1 resistance with TDF/TDF (BIII).
**Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)**

<table>
<thead>
<tr>
<th>Class adverse effects</th>
<th>Lactic acidosis and hepatotoxicity</th>
</tr>
</thead>
</table>

**Abacavir (Ziagen®, ABC)**

- **(ub-HA-ah-vir)**
- **Dosing form:** 250 mg tab, 200 mg/mL soln (240 mL/bottle)
- **Adult dose:**
  - 200 mg bid or 600 mg once daily
  - **NOTE:** Perform HLA-B*5701 test prior; only use if negative

**Important Points:**
- **Contraindication:** Alcohol ABD levels 41%, potential for adverse effects
- **Dosage form:** Tablets with multiple CV risk factors
- **ALERT:** H2R (2.9%), characterized by sign/symptoms from 2 groups:
  - Group 1: Sparing of intrahepatic bile ducts, pseudolymphoma, fatty, or acholiasis
  - Group 2: dyspnea, cough, or pharyngitis (in 4-6 wks). Discontinue drug promptly and DO NOT RESTART!

**Didanosine (Videx®, Videx EC)**

- **(vi-DAYN-uh-see)**
- **Dosing form:** 250 mg tab, 200 mg/mL soln (170 mL/bottle)
- **Adult dose:**
  - 200 mg cap or 240 mg (24 mL) soln once daily
  - Abrupt withdrawal can cause chronic active Hep B flares

**Important Points:**
- **Dosage form:**
  - Intrapartum: 2 mg/kg IV over 1 hr then 1 mg/kg/hr until cord clamping
  - Adult dose: 300 mg po bid or 600 mg po once daily

**Emtricitabine (Emtriva®, FTC)**

- **NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS**

**Lamivudine (Epivir®, 3TC)**

- **(ла-MEE-vee-dee)**
- **Dosing form:** 150 mg, 300 mg tab, 1 mg/mL soln (240 mL/bottle)
- **Adult dose:**
  - 150 mg, 150 mg po once daily or 300 mg po once daily

**Important Points:**
- **Adult dose:**
  - 1 tab po once daily
  - **NOTE:**
    - Take with a meal
    - Intermittent, weak, non-selective, beta-blockers
    - Hepatic metabolism mostly CYP3A4

**Stavudine (Zerit®, d4T)**

- **(ста-ВУД-и-ne)**
- **Dosing form:** 40 mg/mL (10 mL/bottle)
- **Adult dose:**
  - 40 mg/mL sodium (4 mL/bottle)
  - 40 mg/mL sodium (10 mL/bottle)
  - 40 mg/mL sodium (4 mL/bottle)

**Zidovudine (Retrovir®, AZT, ZDV)**

- **(зиДО-вуД-и-ne)**
- **Dosing form:** 300 mg tab, 100 mg/mL (95 mL/bottle)
- **Adult dose:**
  - 200 mg bid or 600 mg po once daily

**Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)**

<table>
<thead>
<tr>
<th>Class adverse effects</th>
<th>Nervous, Myelosuppression, Hypersensitivity, Hepatitis, Non-competing*</th>
</tr>
</thead>
</table>

**Nevirapine (Viramune®, Viramune® AR, NVP)**

- **HAART-ah-vir-nee**
- **Dosing form:**
  - 250 mg tab, 400 mg tab (XR)
  - 10 mg/mL susp (240 mL bottle)
  - 150 mg tab, 200 mg tab (XR)

**Rilpivirine (Edurant®, RPV)**

- **(рил-пи-ВИР-и-ne)**
- **Dosing form:**
  - 25 mg tab, 25 mg susp (96 mL/bottle)

**Lopinavir (Complera®, COB, LPV)**

- **(lo-PI-nay-veer)**
- **Dosing form:** 150 mg once daily

**Lopinavir/ritonavir (Kaltra®, KAL, LPV/RTV)**

- **37. Once daily dosing should not be used in pregnant women.
- **Dosage form:** 2 tabs (400/100 mg) po bid (PI-naive or PI-expl or pl or pl plus 4 tabs (600/200 mg) po once daily (Pl-naive or P-lv) or pl or pl plus

**Nevirapine/ritonavir (Kaltra®, KAL, LPV/RTV)**

- **(kal-TRA)**
- **Dosing form:** 200/1050 mg, 2000/1050 mg tab

**Ritonavir (Norvir®, RTV)**

- **(рит-НАV-ri)**
- **Dosing form:**
  - 100 mg tab, 100 mg susp (240 mL/bottle)

**Pils (Continued)**

- **Dosage form:**
  - 100 mg tab, 200 mg tab (XR) (FTC) + 300 mg tenofovir (TDF) 1 tab po once daily (FTC) + 300 mg tenofovir (TDF)

**Atazanavir (Reyataz®, ATV)**

- **(at-ZA-nay-veer)**
- **Dosing form:** 300 mg + RTV 100 mg po once daily (ARV-naive or exp with ≤ 3 significant mutations)

**Ritonavir (Norvir®, RTV)**

- **(рит-НАV-ri)**
- **Dosing form:** 100 mg tab, 100 mg susp (240 mL/bottle)

**Protease Inhibitors (PIs)**

<table>
<thead>
<tr>
<th>Class adverse effects</th>
<th>Lipid/lipodystrophy, muscle (naive, exp, or with TDF)</th>
</tr>
</thead>
</table>

**Aplaviro (Apvira, APV)**

- **(а-plа-vee-ro)**
- **Dosing form:**
  - 800 mg/mL soln (95 mL/bottle)

**Darunavir (Prezista®, DRV)**

- **(dar-Ун-а-вир)**
- **Dosing form:** 400 mg/mL (96 mL bottle)

**Fosamprenavir (Lexiva®, FPV)**

- **(fa-sam-пре-на-вир)**
- **Dosing form:**
  - 700 mg tab, 50 mg/mL susp (225 mL/bottle)

**Lopinavir + ritonavir Use with caution and with the recommendation**

- **(lo-ПI-nay-veer)**
- **Dosing form:**
  - 150 mg once daily

**Ritonavir (Norvir®, RTV)**

- **(рит-НАV-ri)**
- **Dosing form:** 100 mg once daily

**Stavudine (Zerit®, d4T)**

- **(ста-ВУД-и-ne)**
- **Dosing form:**
  - 40 mg/mL sodium (95 mL/bottle)

**Nevirapine (Viramune®, Viramune® AR, NVP)**

- **HAART-ah-vir-nee**
- **Dosing form:** 200 mg tab, 400 mg tab (XR)

**Rilpivirine (Edurant®, RPV)**

- **(рил-пи-ВИР-и-ne)**
- **Dosing form:**
  - 25 mg tab, 25 mg susp (96 mL/bottle)

**Lopinavir + ritonavir Use with caution and with the recommendation**

- **(lo-ПI-nay-veer)**
- **Dosing form:**
  - 100 mg tab, 100 mg susp (240 mL/bottle)

**Protease Inhibitors (PIs)**

<table>
<thead>
<tr>
<th>Class adverse effects</th>
<th>Lipid/lipodystrophy, muscle (naive, exp, or with TDF)</th>
</tr>
</thead>
</table>

**Aplaviro (Apvira, APV)**

- **(а-plа-vee-ro)**
- **Dosing form:**
  - 800 mg/mL soln (95 mL/bottle)

**Darunavir (Prezista®, DRV)**

- **(dar-Ун-а-вир)**
- **Dosing form:** 400 mg/mL (96 mL bottle)

**Fosamprenavir (Lexiva®, FPV)**

- **(fa-sam-пре-на-вир)**
- **Dosing form:**
  - 700 mg tab, 50 mg/mL susp (225 mL/bottle)

**Lopinavir + ritonavir Use with caution and with the recommendation**

- **(lo-ПI-nay-veer)**
- **Dosing form:**
  - 150 mg once daily

**Ritonavir (Norvir®, RTV)**

- **(рит-НАV-ri)**
- **Dosing form:** 100 mg once daily